Oliver Kornmann

Frankfurt Am Main, HE, Germany

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications

Neurological effects of encapsulated dexamethasone sodium phosphate in children aged 6-9 years with ataxia telangiectasia (NEAT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Neurological effects of encapsulated dexamethasone sodium phosphate in children aged 6-9 years with ataxia telangiectasia (NEAT): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial.

Journal: The Lancet. Child & adolescent health
Published: March 11, 2026

A randomised controlled trial of EP395, a novel anti-inflammatory macrolide, in stable COPD patients.

A randomised controlled trial of EP395, a novel anti-inflammatory macrolide, in stable COPD patients.

Journal: ERJ open research
Published: June 08, 2025

CHF6523 data suggest that the phosphoinositide 3-kinase delta isoform is not a suitable target for the management of COPD.

CHF6523 data suggest that the phosphoinositide 3-kinase delta isoform is not a suitable target for the management of COPD.

Journal: Respiratory research
Published: June 11, 2024

Reduction of SARS-CoV-2 viral load in exhaled air by antiseptic chewing gum: a pilot trial.

Reduction of SARS-CoV-2 viral load in exhaled air by antiseptic chewing gum: a pilot trial.

Journal: Infection
Published: August 08, 2022

Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.

Inhaled anti-TSLP antibody fragment, ecleralimab, blocks responses to allergen in mild asthma.

Journal: The European respiratory journal
Published: June 10, 2022

Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET.

Health outcomes after stopping long-term mepolizumab in severe eosinophilic asthma: COMET.

Journal: ERJ open research
Published: June 24, 2021

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study).

Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study).

Journal: The European respiratory journal
Published: February 08, 2021

Corrigendum to "Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)" [Respir. Med. 170 (Aug-Sep 2020) 106021].

Corrigendum to "Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON)" [Respir. Med. 170 (Aug-Sep 2020) 106021].

Journal: Respiratory medicine
Published: October 21, 2020

COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type-2 and PDE4 gene expression in sputum.

COPD patients with chronic bronchitis and higher sputum eosinophil counts show increased type-2 and PDE4 gene expression in sputum.

Journal: Journal of cellular and molecular medicine
Published: September 26, 2020

Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.

Cardiovascular safety of mometasone/indacaterol and mometasone/indacaterol/glycopyrronium once-daily fixed-dose combinations in asthma: pooled analysis of phase 3 trials.

Journal: Respiratory medicine
Published: August 13, 2020

Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).

Fixed-dose combination of indacaterol/glycopyrronium/mometasone furoate once-daily versus salmeterol/fluticasone twice-daily plus tiotropium once-daily in patients with uncontrolled asthma: A randomised, Phase IIIb, non-inferiority study (ARGON).

Journal: Respiratory medicine
Published: March 13, 2020

COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition.

COPD sputum eosinophils: relationship to blood eosinophils and the effect of inhaled PDE4 inhibition.

Journal: The European respiratory journal
Published: February 04, 2020
Showing 1-12 of 24

Last Updated: 09/26/2026